Pfizer Inc. (NYSE:PFE) Shares Sold by Hurlow Wealth Management Group Inc.

Hurlow Wealth Management Group Inc. trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 18.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,745 shares of the biopharmaceutical company’s stock after selling 1,746 shares during the quarter. Hurlow Wealth Management Group Inc.’s holdings in Pfizer were worth $215,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Advisor OS LLC lifted its position in shares of Pfizer by 1.0% in the 4th quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock worth $1,013,000 after buying an additional 365 shares during the last quarter. Safeguard Investment Advisory Group LLC lifted its holdings in Pfizer by 3.9% in the fourth quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock worth $288,000 after acquiring an additional 371 shares during the last quarter. Lantz Financial LLC boosted its stake in Pfizer by 1.3% in the first quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock valued at $849,000 after acquiring an additional 381 shares during the period. King Wealth Management Group boosted its stake in Pfizer by 2.4% in the fourth quarter. King Wealth Management Group now owns 16,686 shares of the biopharmaceutical company’s stock valued at $480,000 after acquiring an additional 388 shares during the period. Finally, Advance Capital Management Inc. grew its holdings in shares of Pfizer by 4.0% during the fourth quarter. Advance Capital Management Inc. now owns 10,177 shares of the biopharmaceutical company’s stock valued at $293,000 after purchasing an additional 391 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently issued reports on PFE. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Wednesday. Morgan Stanley boosted their price target on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Ten research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $35.86.

Pfizer Price Performance

PFE stock traded up $0.38 during trading hours on Thursday, hitting $27.80. 27,944,899 shares of the stock traded hands, compared to its average volume of 40,970,031. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The stock has a 50-day simple moving average of $27.81 and a 200 day simple moving average of $27.69. Pfizer Inc. has a one year low of $25.20 and a one year high of $37.80. The company has a market cap of $157.53 billion, a P/E ratio of -458.26, a P/E/G ratio of 1.10 and a beta of 0.70.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.26. The company had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm’s revenue was down 19.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.23 earnings per share. Equities analysts forecast that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 6.04%. Pfizer’s dividend payout ratio is presently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.